bottom buying

While biotechs seem out of favour, it looks like some potential here with the amount of protein products apollo have.

Cost of Arthritis Soars, According to New Study
A new study has found that there has been a rapid increase in the impact of
arthritis on individuals, carers and taxpayers to the tune of $24 billion annually.
While the study’s results – released in August by Arthritis Australia – are
alarming, the good news is that investment in prevention and treatment is
highly cost-effective.
According to the study, almost 4 million Australians have arthritis and – if you
are over 80 – the chances of having arthritis are one in two. Of the $24 billion
that the disease costs each year in health care, lost time at work, shortened
life-span and years spent with disability, more than 60% is carried by the
people with arthritis themselves.
While the figure of 3.85 million Australians with arthritis is concerning enough, it is the rapid rise – of
about 700,000 in just six years – that is the most disturbing. More than half of these people are of
working age, according to the study done by Access Economics – and the cost to the community has
skyrocketed more than $4 billion in just three years.
The President of Arthritis Australia, Dr Mona Marabani, said that the disease is a greater health priority
than cancer or diabetes. “Yet because arthritis isn’t perceived to kill people, it's not taken as seriously,”
she said.
However, the report also found that clinical evidence suggests that the timely use of medicines can arrest
joint damage and consequent disability. The finding highlighted the importance of Apollo's research into
developing a drug that can both reduce the pain of arthritis and be taken in tablet form rather than
injection, further reducing the health costs of treatment.
Earlier this year, Apollo announced the development of an oral treatment that appears to reduce
inflammation in the joints, a key factor in the pain associated with arthritis. Preclinical studies revealed
that oral doses of Apollo's TNF blocker ALS-00T2 were as good as an injection in lowering inflammation in
animals.
The results were important because they also showed that Apollo's Oradel™ technology can be used to
deliver a large drug, such as ALS-00T2. A major drawback of large drugs is that they are usually
destroyed by the stomach’s acid, when taken orally – leaving injections as the only form of administration.
Apollo CEO, John Priest, said the study revealed that new medicines are an even greater priority. "At one
level this means that there is an enormous market for the Apollo therapy. However there is also the
alarming consideration that this is a disease that is rapidly on the rise amongst Australians "in their
working prime"," he said.
"This just reinforces how important the Apollo anti-arthritis drug could be both to the Australian economy
and also to individual Australian either with the disease or caring for someone with arthritis."